Imaging shows inflammation and toxin link in MS models

Credibility

Interest

Share:2 min read

Key Takeaway

Advanced PET and MRI scans can spot active inflammation linked to a harmful chemical called acrolein in MS-like models, helping track disease activity inside the brain and spine.

What They Found

Researchers used two imaging methods (MRI and PET) that show where a pro-inflammatory enzyme called myeloperoxidase (MPO) is active; MPO is made by immune cells and can drive inflammation. They found MPO activity in the brains and spinal cords of mice with MS-like disease, especially during the active (acute) stage, and it fell at later stages. The MRI method could find smaller spots of MPO activity, like a close-up camera finding small details, while PET showed larger overall areas of activity, like a wide-angle view. Levels of MPO and tissue acrolein-adducts (acrolein is a reactive chemical that can damage cells; an “adduct” means it has stuck to proteins) matched each other in tissue, showing a link between MPO activity and acrolein buildup in affected areas. Blood levels of acrolein-adducts did not reliably match what was happening in the brain and spinal cord, so blood tests alone might miss ongoing damage inside the nervous system.

Who Should Care and Why

People with MS and their caregivers should care because these imaging methods could help doctors see where active inflammation and chemical damage are happening inside the nervous system, like using a heat map to find hot spots. Neurologists and MS care teams may use this kind of imaging to monitor whether treatments are reducing active inflammation, similar to checking if a fever is down after medicine. Patients in relapsing or progressive phases might benefit most, since the scans showed changes during active disease and later stages. Caregivers can think of imaging like a window into the nervous system that helps explain symptoms (for example, new weakness or numbness) when ordinary blood tests don’t show the problem. Knowing if inflammation and acrolein are active could guide decisions about switching or adjusting treatments, much like using a traffic app to choose a faster route when roads are blocked.

Important Considerations

The study was done in mouse models of MS, not in people, so findings may not work exactly the same in humans. Blood (serum) acrolein-adducts did not reliably reflect what was happening in brain or spinal cord tissue, so a simple blood test may not tell the whole story. Stopping MPO did not quickly lower tissue acrolein, suggesting damage can persist for days and that monitoring over time is needed to see treatment effects.

AI-generated summary — for informational purposes only, not medical advice

Categories:

Early Research MS Diagnostics Treatment Updates

Article Topics:

AcroleinExperimental autoimmune encephalomyelitis (EAE)Multiple sclerosis (MS)Myeloperoxidase (MPO)[(18)F]MAPP-PETheMAMP-MRI

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like NeuroImage often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News